Christopher Wilson

Senior Associate

[email protected]

Washington, D.C.

P: +1.202.639.7739
F: +1.202.585.1058
Christopher Wilson

Christopher Wilson is a senior associate in Baker Botts' Antitrust and Competition Practice group. His practice focuses on civil antitrust, intellectual property, and other complex commercial actions. Mr. Wilson has extensive experience in representing litigants from complaint filing through trial, as well as in advising corporate clients on a variety of antitrust matters, particularly with respect to parent/subsidiary issues, resale price maintenance, the Robinson-Patman Act, and compliance matters. He has represented and advised clients in a number of industries, including industrial manufacturing, telecommunications, pharmaceuticals, retail, and healthcare manufacturing.

Mr. Wilson has been a key member of legal teams for Fortune 500 clients defending against Sherman Act class action claims, including in cases that were granted favorable judgments at the motion to dismiss and summary judgment stages. He also has extensive experience defending pharmaceutical companies in patent infringement and antitrust actions, as well as representing generic pharmaceutical manufacturers in Hatch-Waxman Act litigation. In each of these cases, Mr. Wilson was deeply involved in setting case strategy, preparing dispositive and other critical filings, managing discovery, taking depositions, and negotiating with opposing counsel.

Mr. Wilson is currently co-chair of the ABA Section of Litigation’s Antitrust Litigation Committee, and formerly served as co-chair of the Section of Litigation’s Consumer Litigation Committee.

Mr. Wilson graduated from Stanford Law School, where he served as President of the Stanford Black Law Students Association and participated in legal clinics directed to criminal defense and public education law. He received his undergraduate degree from Penn State University, where he was a Schreyer Honors Scholar and played running back and fullback for the university's football team.

Related Experience

  • Representing major pharmaceutical company in in antitrust class action involving a blockbuster biologic drug, where class plaintiffs have alleged reverse-payment settlement agreements between the brand and biosimilar manufacturers, and also that the brand amassed a "patent thicket" of over 100 patents that forestalled competition.
  • Representing major generic pharmaceutical companies in one of the largest-ever antitrust class actions, currently pending as multi-district litigation brought by state attorneys general, individual, direct action plaintiffs, and putative classes of direct, intermediate, and end purchaser plaintiffs.
  • Representing major generic pharmaceutical company in antitrust action brought in involving alleged sham litigation and misuse of Hatch-Waxman regulatory scheme.
  • Represented industrial manufacturer in a class action alleging a Section 1 price-fixing conspiracy;  granted a favorable ruling on summary judgment, which was affirmed on appeal.
  • Represented healthcare manufacturers in a class action alleging a Section 1 price-fixing conspiracy; granted a favorable judgment on a motion to dismiss the original consolidated complaint.
  • Represented generic pharmaceutical manufacturers in Hatch-Waxman Act litigation; was deeply involved in negotiating settlements as well as in representing clients through trial.
  • Represented manufacturer in a civil action that initially asserted antitrust and various common law claims; the plaintiff voluntarily dismissed the antitrust claim rather than responding to a motion to dismiss directed to that claim.
  • Represented a mother and child in a pro bono action against a state department of family services, alleging violations of the mother's and child's constitutional rights; granted a six-figure monetary settlement for the mother and child, as well as extensive policy changes within the state department.

Awards & Community

Recognized as a "Rising Star" by The Legal 500 U.S., 2022

Recognized as a Washington D.C. Super Lawyer-Rising Star (Thomson Reuters), 2022

News

results Page of

Thought Leadership

results Page of